洞察原胺和胰岛素利斯普罗之间的分子间相互作用
Guangqi Wang1, Qingyu Wang2, Hongru Zhu3
1School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe, Shenyang 110016, People's Republic of China; Tonghua Dongbao Pharmaceutical Co., Ltd, No. 11 Donghuan Beilu BDA, Beijing 100176, People's Republic of China.
Bioorganic chemistry
|January 31, 2025
概括
蛋白胺与胰岛素利斯普罗 (IL) 结合,延长其作用. 2表现出最强的结合亲和力,由力驱动,增强对药物输送中的蛋白胺-IL相互作用的理解.
科学领域:
- 药理学和生物化学 药理学和生物化学
- 蛋白质 - 连接体相互作用
- 药物输送系统 药物输送系统
背景情况:
- 质氨酸与胰岛素利斯普罗 (IL) 形成复合体,以延长其低血糖作用.
- 蛋白胺和IL之间的精确结合机制尚未完全理解.
- 了解这些相互作用对于优化胰岛素配方至关重要.
研究的目的:
- 阐明原胺成分和胰岛素利斯普罗 (IL) 之间的结合机制.
- 确定哪种蛋白胺表现出与IL最强的结合亲和力.
- 探索对原胺-IL复合体形成的结构和能量贡献.
主要方法:
- 逆相高性能液态色谱 (RP-HPLC) 用于评估结合能力.
- 异热定位热度计 (ITC) 用于确定结合热力学.
- 表面等离子体共振 (SPR) 分析结合动力学.
- 生物信息学分析和分子动力学 (MD) 模拟以调查相互作用细节.
主要成果:
- 蛋白胺的结合能力各不相同,其中2 (P2) 对IL的亲和力最高.
- ITC揭示了P2与IL (ΔH = -149 ± 2.24 kJ/mol) 的度驱动的结合模式.
- SPR显示了原胺-IL复合物的快速关联和缓慢解离合动力学.
- 生物信息学和MD模拟突出了键和静电相互作用的重要性,之间存在明显的差异.
结论:
- 2表现出对胰岛素利斯普罗最强的结合亲和力,这表明它有可能用于增强胰岛素配方.
- 结合主要是以力驱动的,涉及显著的结合和静电相互作用.
- 这项多视角研究提供了对原胺-IL相互作用的更深入的机制理解,支持区域结合模型.
相关概念视频
Insulin Formulations: Types and Delivery
162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
162
Insulin: Biosynthesis, Chemistry, and Preparation
346
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
346
Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
Factors Affecting Protein-Drug Binding: Drug Interactions
90
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
90
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K


